指南与共识其他结缔组织病

系统性硬化症相关间质性肺病的识别与管理:欧洲循证共识声明

The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements.
指南 / 共识 · Lancet Rheumatol · 2020-01-14

该共识采用改良Delphi法,由27名欧洲专家经三轮线上调查、面对面讨论及两轮补充Delphi建立系统性硬化症相关间质性肺病(SSc-ILD)管理共识,覆盖风险因素、筛查、诊断与严重度评估、治疗启动与选择、疾病进展及治疗升级六个领域,达成52条主要声明和6条补充声明,并定义临床管理算法。

要点

  • 所有系统性硬化症患者均应使用高分辨率CT筛查SSc-ILD。
  • 高分辨率CT是诊断SSc-ILD的主要工具,肺功能检查支持筛查与诊断。
  • SSc-ILD严重度需用多个指标评估;所有严重病例均适合治疗。

核心结论

  • 通过稳健的改良Delphi流程,建立了首个关于SSc-ILD识别与内科管理的循证共识声明。

研究设计与样本

  • 采用基于系统文献分析的改良Delphi法,由27名欧洲肺科、风湿科和内科专家参与三轮线上调查、面对面讨论、WebEx会议及两轮补充Delphi。
  • 共识达成标准为至少80%专家组成员表示同意或不同意。

主要发现

  • 2018年7月1日至2019年8月27日期间,六个管理领域共达成52条主要声明和6条补充声明,并定义了临床实践算法。
  • 对临床使用最重要的共识包括:所有SSc患者应使用高分辨率CT筛查SSc-ILD;高分辨率CT是诊断SSc-ILD的主要工具;肺功能检查支持筛查和诊断。
  • SSc-ILD严重度应用多个指标测量;所有严重病例均适合治疗;部分患者可不进行药物治疗;随访评估可识别疾病进展;进展速度与疾病严重度共同驱动治疗升级决策。

关键数值与推荐

  • 共识达成阈值:至少80%专家组成员同意或不同意。
  • 所有系统性硬化症患者均应使用高分辨率CT筛查SSc-ILD。
  • 高分辨率CT是诊断SSc-ILD的主要工具,肺功能检查支持筛查与诊断。
  • SSc-ILD严重度应使用多个指标测量,所有严重病例均适合治疗。
  • 部分患者可不进行药物治疗;随访评估识别疾病进展,进展速度与严重度共同驱动治疗升级。

临床怎么用

  • 临床中应对所有系统性硬化症患者使用高分辨率CT筛查SSc-ILD,并结合肺功能检查支持诊断。
  • 采用多个指标评估SSc-ILD严重度,对严重病例考虑治疗,部分患者可选择不进行药物治疗。
  • 通过随访评估识别疾病进展,根据进展速度和疾病严重度决定是否升级治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Systemic sclerosis-associated interstitial lung disease (ILD) carries a high mortality risk; expert guidance is required to aid early recognition and treatment. We aimed to develop the first expert consensus and define an algorithm for the identification and management of the condition through application of well established methods. METHODS: Evidence-based consensus statements for systemic sclerosis-associated ILD management were established for six domains (ie, risk factors, screening, diagnosis and severity assessment, treatment initiation and options, disease progression, and treatment escalation) using a modified Delphi process based on a systematic literature analysis. A panel of 27 Europe-based pulmonologists, rheumatologists, and internists with expertise in systemic sclerosis-associated ILD participated in three rounds of online surveys, a face-to-face discussion, and a WebEx meeting, followed by two supplemental Delphi rounds, to establish consensus and define a management algorithm. Consensus was considered achieved if at least 80% of panellists indicated agreement or disagreement. FINDINGS: Between July 1, 2018, and Aug 27, 2019, consensus agreement was reached for 52 primary statements and six supplemental statements across six domains of management, and an algorithm was defined for clinical practice use. The agreed statements most important for clinical use included: all patients with systemic sclerosis should be screened for systemic sclerosis-associated ILD using high-resolution CT; high-resolution CT is the primary tool for diagnosing ILD in systemic sclerosis; pulmonary function tests support screening and diagnosis; systemic sclerosis-associated ILD severity should be measured with more than one indicator; it is appropriate to treat all severe cases; no pharmacological treatment is an option for some patients; follow-up assessments enable identification of disease progression; progression pace, alongside disease severity, drives decisions to escalate treatment. INTERPRETATION: Through a robust modified Delphi process developed by a diverse panel of experts, the first evidence-based consensus statements were established on guidance for the identification and medical management of systemic sclerosis-associated ILD. FUNDING: An unrestricted grant from Boehringer Ingelheim International.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Hoffmann-Vold AM, Maher TM, Philpot EE, et al. The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. Lancet Rheumatol. 2020. PMID: 38263663. doi:10.1016/S2665-9913(19)30144-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。